Review of Sorafenib data at the 2005 Annual Meeting of the American Society of Clinical Oncology (ASCO)

May 13 to May 17, 2005

Tuesday, May 17, 2005:
Investor Conference Call ASCO Review 2005

The audio recording of this event is no longer available.

Fact Sheets and Background Information
Sorafenib Clinical Program OverviewDownload ( PDF, 120 KB ) collect
Sorafenib Fact SheetDownload ( PDF, 139 KB ) collect
Renal Cell Carcinoma Fact SheetDownload ( PDF, 114 KB ) collect
Hepatocellular Carcinoma Fact SheetDownload ( PDF, 138 KB ) collect
Melanoma Fact SheetDownload ( PDF, 119 KB ) collect
Sorafenib at ASCO 2005Download ( PDF, 119 KB ) collect

Abstracts and Oral Presentations on Sorafenib at ASCO 2005

Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC) ( Abstract No: LBA4510)

Final findings from a phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC) ( Abstract No: 4544 )

A phase II study of BAY 43-9006 in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal cancer (NPC) ( Abstract No: 5566)

Phase I trial of BAY 43-9006 (sorafenib) combined with dacarbazine (DTIC) in metastatic melanoma patients ( Abstract No: 7508)

Phase I/II, pharmacokinetic and pharmacodynamic trial of BAY 43-9006 alone in patients with metastatic melanoma ( Abstract No: 3037)

A phase I study of BAY 43-9006 and gefitinib in patients with refractory or recurrent non-small-cell lung cancer (NSCLC) ( Abstract No: 3067)

Pharmacodynamic study of BAY 43-9006 in patients with metastatic renal cell carcinoma ( Abstract No: 3005)

Doppler ultrasonography with perfusion software and contrast agent injection as a tool for early evaluation of metastatic renal cancers treated with the Raf kinase and VEGFR inhibitor: A prospective study ( Abstract No: 3069)

Useful Links:

ASCO Homepage:

Clinical trials information:

American Cancer Society:

Information on renal cell cancer:

Information on liver cancer:

Information on melanoma:

Information on cancer incidence, prevalence and mortality (GLOBOCAN):

Last updated: January 13, 2014 Copyright © Bayer AG